A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

NCT00542386 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

642

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Dialysis
Hyperphosphatemia
Dyslipidemia

Interventions

DRUG: MCI-196
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation